Top Picks For 2025: Skye Bioscience
February 02, 2025 at 14:20 PM EST
Skye Bioscience is developing a peripheral restricted CB1 antibody to treat obesity by restoring leptin sensitivity and increasing fat metabolism, while avoiding the CB1-induced THC/neuro side effects. This has significant potential.
